Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

EXHIBIT 10.22    
    

 
 

SCHEDULE TO INDEMNIFICATION AGREEMENT    
    

        The following is a list of the current directors and senior executive officers of Genzyme Corporation who are party to an Indemnification Agreement, the form of
which was filed as Exhibit 10.34 to our 1990 Form 10-K: 

        Constantine
E. Anagnostopoulos; Mara G. Aspinall; Mark R. Bamforth; Douglas A. Berthiaume; Henry E. Blair; Robert J. Carpenter; Earl M. Collier, Jr.; Charles L. Cooney; Zoltan A. Csimma;
Thomas J. DesRosier; Richard H. Douglas; Victor J. Dzau; David D. Fleming; Georges A. Gemayel; James A. Geraghty; Elliott D. Hillback, Jr.; Alison F. Lawton; Evan M. Lebson; Roger Louis; Connie Mack
III; Mary McGrane; John M. McPherson; C. Ann Merrifield; Richard A. Moscicki; Donald E. Pogorzelski; Alan E. Smith; Sandford D. Smith; Henri A. Termeer; Peter T. Traynor; G. Jan van Heek; Peter Wirth;
and Michael S. Wyzga. 

QuickLinks

EXHIBIT 10.22

SCHEDULE TO INDEMNIFICATION AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

 
 

EXHIBIT 10.23    
    

 
 

SCHEDULE TO EXECUTIVE SEVERANCE AGREEMENT    
    

        The following is a list of our senior executive officers who are party to an Executive Severance Agreement, the form of which was filed as Exhibit 10.2 to
our Form 10-Q for the quarter ended June 30, 2002: 

        Mara
G. Aspinall; Mark R. Bamforth; Earl M. Collier, Jr.; Zoltan A. Csimma; Thomas J. DesRosier; Richard H. Douglas; David D. Fleming; Georges A. Gemayel; James A. Geraghty; John V.
Heffernan; Elliot D. Hillback, Jr.; Alison F. Lawton; Mary McGrane; David J. McLachlan; John M. McPherson; David P. Meeker; C. Ann Merrifield; Richard A. Moscicki; Donald E. Pogorzelski; Alan E.
Smith; Sandford D. Smith; G. Jan van Heek; and Michael S. Wyzga. 

        We
are a party to Executive Severance Agreements with the executive officers named above, under which payments will be made under certain circumstances following a Change of Control of
the Company (as defined in the Executive Severance Agreements). The Executive Severance Agreements provide that in the event the officer's employment is terminated by the Company Without Cause (as
defined) or by the officer for Good Reason (as defined) following a Change of Control, the Company will make a lump sum severance payment to the officer of up to two times annual salary and bonus.
Upon such termination, the Executive Severance Agreements also provide for (i) a cash payment equal to the additional retirement benefit which would have been earned under the Company's
retirement plans if employment had continued for two years following the date of termination, (ii) participation in the life, accident and health insurance plans of the Company for such period
except to the extent such benefits are provided by a subsequent employer and (iii) in certain circumstances, legal costs and expenses associated with such termination. 

QuickLinks

EXHIBIT 10.23

SCHEDULE TO EXECUTIVE SEVERANCE AGREEMENT<Page>

                                                               Exhibit 10.34.1

                                  2ND AMENDMENT
                        CONTRACT MANUFACTURING AGREEMENT

THIS AMENDMENT NUMBER 2 dated as of October 9, 2002 (the "2nd Amendment") is
made by and between The Dow Chemical Company, a Delaware corporation ("Dow") and
GelTex Pharmaceuticals, Inc., a Massachusetts corporation ("GelTex"). The
parties wish to amend the Contract Manufacturing Agreement they entered into
effective September 4, 2001 ("Agreement") as hereafter set forth. Capitalized
terms not defined herein shall have the respective meanings ascribed to them in
the Agreement.

                                    RECITALS

WHEREAS, Dow and GelTex have previously entered into the Agreement and
subsequent Amendment One to this agreement, whereby Dow, in connection with its
obligation to manufacture and supply Product to GelTex, presently maintains an
annual Product manufacturing capacity level at the Dow Facility of [**] and
Genzyme has committed to purchase a minimum of [**];

WHEREAS, GelTex desires to increase its purchase commitment to a minimum of [**]
and Dow is willing to supply this additional quantity.

NOW THEREFORE, in consideration of the premises and of the covenants herein
contained, Dow and GelTex hereby agree as follows:

1.   GelTex commits to purchase a minimum of [**] and Dow agrees to supply this
     volume.

2.   The purchase price will be now calculated as follows:

     [**]

3.   GelTex may request additional volumes in this period should they so desire.
     Dow shall at all times during 2002 and 2003 retain sufficient capacity to
     supply up to [**] should such amounts be requested. In the event that
     GelTex requests quantities in excess of [**], Dow shall make reasonable
     commercial efforts to supply these additional volumes, subject to the plant
     being able to supply these volumes without undue cost being incurred by
     Dow.

4.   The parties acknowledge that it is GelTex's current expectation to purchase
     [**]. However, both parties agree that this is only a current expectation,
     but not an obligation.

5.   Both parties agree to revoke the average pricing letter dated 2nd July
     2002, and Dow will reconcile the sales revenue differences on product
     shipped to date between the terms of the average pricing letter and the
     price as described in 2 above. Monies owing by GelTex

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed
separately with the commission.

<Page>

     will be paid in full within fifteen (15) days following presentation of a
     miscellaneous invoice, and any support that may reasonably be requested by
     GelTex.

6.   The parties will continue to discuss the possibility of entering into a
     purchase agreement for the supply of [**].

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed
separately with the commission.

<Page>

     IN WITNESS WHEREOF, the parties hereto have caused this Amendment Number 2
to be executed by their duly authorized representatives effective as of the date
set forth above.

     THE DOW CHEMICAL COMPANY

     By:    /s/ GG Bompa

     Name:  GG Bompa

     Title: Commercial Director

     GELTEX PHARMACEUTICALS, INC.

     By:    /s/ Edmund Sybertz

     Name:  Edmund Sybertz

     Title: Senior VP and General Manager

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed
separately with the commission.<Page>

                                                               Exhibit 10.34.2

                                 THIRD AMENDMENT
                        CONTRACT MANUFACTURING AGREEMENT

THIS AMENDMENT NUMBER 3 dated as of December 8, 2003 (the "3rd Amendment") is
made by and between The Dow Chemical Company, a Delaware corporation ("Dow") and
Genzyme Corporation, a Massachusetts corporation ("Genzyme"). The parties wish
to amend the Contract Manufacturing Agreement they entered into effective
September 4, 2001 ("Agreement") as hereafter set forth. Capitalized terms not
defined herein shall have the respective meanings ascribed to them in the
Agreement.

                                    RECITALS

WHEREAS, Dow and Genzyme have previously entered into the Agreement and
subsequent Amendment One to this agreement, whereby Dow, in connection with its
obligation to manufacture and supply Product to Genzyme, presently maintains an
annual Product manufacturing capacity level at the Dow Facility of [**] and
Genzyme has committed to purchase a minimum of [**];

WHEREAS, Genzyme under Amendment Two to this agreement increased its purchase
commitment to a minimum of [**] and Dow was willing to supply this additional
quantity.

WHEREAS, Genzyme and Dow hereby acknowledge that pursuant to Section 3.1, at a
minimum, the Agreement shall extend for an additional [**],

NOW THEREFORE, in consideration of the premises and of the covenants herein
contained, Dow and Genzyme hereby agree as follows:

  1. Genzyme commits to purchase a minimum of [**] and Dow agrees to supply this
     volume.

  2. The purchase price will be now calculated as follows:

     [**]

  3. Genzyme may request additional volumes in this period should they so
     desire. Dow plans to hold minimum finished product inventory during 2004.
     Thus such additional volumes and delivery dates are to be committed by
     Genzyme before [**].

     -    For all such additional quantities ordered for delivery in 2004, the
          price will be:

          [**]

     -    In the event that Genzyme requests further additional quantities
          during 2004 after [**], a three-month lead time will be required to
          restart the plant. Plant ramp up

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed
separately with the commission.

<Page>

          rate and capacity will influence the rate that additional material can
          be made and delivered.

     -    In the event Genzyme requires the further additional product in a time
          frame sooner than 3 months then Dow shall make reasonable commercial
          efforts to supply these additional volumes sooner than the three
          months. Genzyme agrees to fund extraordinary start up costs that may
          be incurred by Dow to meet an accelerated schedule, subject to these
          costs being agreed by Genzyme before they are expended.

  4. It is the parties intent for Dow to deliver the first [**], Dow would be
     prepared to store any purchase Product for Genzyme (up to the maximum store
     capacity) should Genzyme want to delay shipment, without storage charges up
     to [**], Dow shall invoice Genzyme for any stored Product when the
     Product is ready for shipment and placed in storage pursuant to the mutual
     agreement of the parties, and title and risk of loss for Product in storage
     shall pass to Genzyme on date of the invoice.

This 3rd Amendment is intended to supplement the Agreement and except as
explicitly modified by the terms of this 3rd Amendment, the Agreement as
previously modified, shall continue in full force and effect. The Agreement as
previously modified, and this 3rd Amendment shall constitute the entire
agreement between the parties on the subject matter hereof and shall not be
amended except as provided in Article 33 of the Agreement.

     IN WITNESS WHEREOF, the parties hereto have caused this 3rd Amendment to be
executed by their duly authorized representatives effective as of the date set
forth above.

     THE DOW CHEMICAL COMPANY

     By:    /s/ George J. Biltz

     Name:  George J. Biltz

     Title: VP C & FC

     GENZYME CORPORATION

     By:    /s/ Henri A. Termeer

     Name:  Henri A. Termeer

     Title: CEO

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed
separately with the commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]